WORCESTER, Mass., June 19, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, made a podium presentation of data from a company-sponsored study at The Endocrine Society’s 90th Annual Meeting (ENDO, www.endo-society.org) in San Francisco on June 18, 2008.
